A Phase II Study of Transcatheter Arterial Chemoembolization (TACE) Combined with Anti-PD-1 Antibody (IBI308) in Patients with Advanced Hepatocellular Carcinoma
Latest Information Update: 05 Mar 2025
At a glance
- Drugs Sintilimab (Primary) ; Pirarubicin
- Indications Liver cancer
- Focus Therapeutic Use
- 27 Feb 2025 Status changed from recruiting to completed.
- 12 Sep 2023 Planned End Date changed from 10 May 2023 to 10 May 2024.
- 12 Sep 2023 Planned primary completion date changed from 10 May 2023 to 10 May 2024.